ASU's Justin Bina told the New York Post that people starting GLP-1 drugs become willing to pay more per pound for certain proteins, even as cattle stocks hit a 75-year low.
Recap by typeshit. Full story at New York Post.
Zacks expects $10.1 billion from Mounjaro and $5.1 billion from Zepbound, and notes Lilly plans to seek retatrutide approval in early 2027.
Medicare open enrollment has started, and plan changes include newly negotiated drug prices and lower costs on some medications.
Ireland's drug pricing watchdog found Wegovy gives value for money and recommended the health service consider covering it publicly.
Prescriptions roll out in phases from the 29th, starting at 129,800 won for four weeks. Hanmi reported 9.75% average weight loss at 40 weeks in a phase 3 interim analysis.
A University of Pennsylvania mouse study found on-off GLP-1 use left mice 20 per cent heavier than those kept on the drug, and doctors warn human effects are unknown.
10 News reports Australians are ending up in hospital after using unregulated peptides, prompting warnings from two state health departments.
Loading…